Unlock instant, AI-driven research and patent intelligence for your innovation.

Heterologous Animal Cytokine Mutant Vaccine and Its Application

A technology of animal cells and cytokines, applied in cytokines/lymphokines/interferons, medical raw materials derived from mammals, applications, etc., can solve the problems of high cost, difficult production, hindering the efficacy of anti-cytokine biological preparations, etc.

Active Publication Date: 2016-12-28
北京表源生物技术有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite the medical and commercial success of passive anticytokine immunotherapy, it has several disadvantages: difficult and costly to manufacture, regular infusions required by patients, limited half-life hampering the efficacy of anticytokine biologics, and some side effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterologous Animal Cytokine Mutant Vaccine and Its Application
  • Heterologous Animal Cytokine Mutant Vaccine and Its Application
  • Heterologous Animal Cytokine Mutant Vaccine and Its Application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1. Treatment of rat osteoporosis with human RANKL cytokine mutant hRANKL223+300M

[0063] 1. Human RANKL cytokine mutant hRANKL223+300M in the treatment of osteoporosis in rats

[0064] Human RANKL cytokine mutant hRANKL223+300M is a cytokine hRANKL from human 158-317 obtained by mutation. wxya 158-317 The amino acid sequence of the human RANKL cytokine mutant hRANKL223+300M is shown in SEQ ID No.1. Wherein, the first position of SEQ ID No.1 corresponds to the 158th position of human RANKL cytokine, and the 160th position of SEQ ID No.1 corresponds to the 317th position of human RANKL cytokine. Human RANKL cytokine mutant hRANKL223+300M mutates the arginine at position 223 (66th of SEQ ID No. 7) of human RANKL cytokine to alanine, and mutates the 300th position of human RANKL cytokine (SEQ ID No. 7 The 143rd position) of aspartic acid is alanine.

[0065] 1. Preparation of human RANKL cytokine mutant hRANKL223+300M

[0066] Replace the small fragment betwe...

Embodiment 2

[0101] Example 2, Treating Rat Osteoporosis and Rabbit Osteoporosis with Mouse RANKL Cytokine Mutant mRANKL222+299M

[0102] 1. Mouse RANKL cytokine mutant mRANKL222+299M treats osteoporosis in rats and rabbits

[0103] The amino acid sequence of the mouse RANKL cytokine mutant mRANKL222+299M is SEQ ID No.2. The 1st position of SEQ ID No.2 corresponds to the 158th position of the mouse RANKL cytokine, and the 159th position of SEQ ID No.2 corresponds to the 316th position of the mouse RANKL cytokine. The mouse RANKL cytokine mutant mRANKL222+299M mutates the arginine at position 222 of the mouse RANKL cytokine to alanine, and the aspartic acid at position 299 to alanine.

[0104] 1. Preparation of mouse RANKL cytokine mutant mRANKL222+299M

[0105] Replace the small fragment between SalI and XhoI of the pGEX-6p-1 vector (GE Healthcare, USA) with the gene of the mouse RANKL cytokine mutant mRANKL222+299M shown in SEQ ID No.4 to obtain the gene containing mRANKL222+299M Recom...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a heterogenous animal cytokine mutant vaccine and application thereof. The active composition of the heterogenous animal cytokine mutant vaccine is a heterogenous animal cytokine mutant, and the heterogenous animal cytokine mutant is obtained by performing mutation on cytokine coming from a heterogenous animal. The heterogenous animal cytokine mutant satisfies the following conditions: 1) the cytokine coming from the heterogenous animal can be combined with an acceptor of the above cytokine on a cell membrane in the heterogenous animal; and 2) the combination capacity of the heterogenous animal cytokine mutant with the cytokine on the cell membrane in the heterogenous animal is 1 / 10 or less of the combination capacity of the cytokine of the heterogenous animal with the cytokine on the cell membrane in the heterogenous animal. The heterogenous animal cytokine mutant vaccine is applicable to treat osteoporosis, autoimmune disease or tumor of acceptor animals.

Description

technical field [0001] The invention relates to a heterologous animal cytokine mutant vaccine and its application. Background technique [0002] Many cells in the animal body synthesize and secrete some proteins and small molecule polypeptide substances, which can transmit information between cells and regulate various physiological functions of themselves and other cells. These proteins and small molecule polypeptide substances are collectively called cytokines. The cytokines that have been discovered can be divided into the following categories according to their main functions: 1. Interleukins: play an important regulatory role in intercellular interactions, immune regulation, hematopoietic and inflammatory processes, and more than 30 types have been reported so far; 2. Colony-stimulating factor: stimulates hematopoietic stem cells or hematopoietic cells at different stages of differentiation to form cell colonies; 3. Interferon: interferes with virus infection and replic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/00C07K14/525C07K14/46C12N15/28C12N15/12C12N15/85C12N1/15C12N1/19C12N1/21C12N5/10A61K35/12A61K35/74A61K35/76A61K36/06A61K36/064A61K48/00A61P19/10A61P37/00A61P35/00
Inventor 高斌刘长振赵云峰
Owner 北京表源生物技术有限公司